Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Hoon Lee

Showing results (51-60 of 513) with videos related to

Pageof 52
Sort By:
Cancer Research and Treatment|July 14, 2023
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World DataYoungkyung Jeon, Sehhoon Park, Hyun Ae Jung, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2011
Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmationThi Thanh Hanh Nguyen, Hwa-Ja Ryu, Se-Hoon Lee, et al.
Journal of Clinical Medicine|March 25, 2022
Characterization of Distinct Microbiota Associated with Scalp Dermatitis in Patients with Atopic DermatitisYu Ri Woo, Minah Cho, Yujin Han, et al.
Clinical Lung Cancer|January 27, 2019
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase InhibitorJiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasisSeonggyu Byeon, Jun Soo Ham, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Anticancer Research|January 1, 2015
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancerBhumsuk Keam, Soyeon Kim, Yong-Oon Ahn, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Elife|December 6, 2024
Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burdenHyungtai Sim, Hyun Jung Park, Geun-Ho Park, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
Pageof 52

Showing results (51-60 of 513) with videos related to

Sort By:
Pageof 52
Cancer Research and Treatment|July 14, 2023
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World DataYoungkyung Jeon, Sehhoon Park, Hyun Ae Jung, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2011
Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmationThi Thanh Hanh Nguyen, Hwa-Ja Ryu, Se-Hoon Lee, et al.
Journal of Clinical Medicine|March 25, 2022
Characterization of Distinct Microbiota Associated with Scalp Dermatitis in Patients with Atopic DermatitisYu Ri Woo, Minah Cho, Yujin Han, et al.
Clinical Lung Cancer|January 27, 2019
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase InhibitorJiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasisSeonggyu Byeon, Jun Soo Ham, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Anticancer Research|January 1, 2015
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancerBhumsuk Keam, Soyeon Kim, Yong-Oon Ahn, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Elife|December 6, 2024
Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burdenHyungtai Sim, Hyun Jung Park, Geun-Ho Park, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
Pageof 52